The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients / J. Teitel, E. Berntorp, G. Dolan, K. Fischer, A. Gringeri, C. Kessler, T. Lambert, C. Leissinger, L. Nemes, M. Shima. - In: HAEMOPHILIA. - ISSN 1351-8216. - 17:3(2011 May), pp. 516-521. [10.1111/j.1365-2516.2010.02440.x]
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients
A. Gringeri;
2011
Abstract
The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
